Physician profile
Samir Patel
NPI 1811097595
$4,108.97
in general payments reported to CMS, 2019-2025
20 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $155 · 2021: $687 · 2022: $560 · 2023: $1,539 · 2024: $372 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,148 · Food and Beverage: $1,074 · Education: $51.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,148.42 |
| Food and Beverage | $1,074.19 |
| Education | $51.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,205.11 | 2021-2025 | Inspire |
| Glaxosmithkline, LLC. | $449.75 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $225.96 | 2021-2024 | Tezspire, Fasenra |
| Insmed, INC. | $190.26 | 2022-2025 | Arikayce, Brinsupri |
| La Jolla Pharmaceutical Company | $142.39 | 2020 | |
| Mylan Specialty L.P. | $133.03 | 2019-2023 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $94.96 | 2019 | |
| Jazz Pharmaceuticals INC. | $87.35 | 2019 | |
| United Therapeutics Corporation | $82.51 | 2021 | |
| Amgen INC. | $72.14 | 2022-2025 | Tezspire |
| Medtronic Vascular, INC. | $71.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.48 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Electromed, INC. | $63.49 | 2023-2024 | Smartvest |
| Genzyme Corporation | $57.32 | 2022-2023 | |
| Itamar Medical INC | $41.94 | 2024 | Watchpatone |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.61 | 2024 | Jynarque |
| Phadia US INC. | $31.42 | 2022 | |
| Abbott Laboratories | $23.79 | 2023 | 2nd Gen Centrimag Primary Console |
| Takeda Pharmaceuticals U.S.A., INC. | $20.91 | 2022 | |
| Merck Sharp & Dohme LLC | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.